Osigraft Study: a prospective, randomised, controlled, multicentre, (pilot) study of Osigraft® in instrumented posterolateral fusions

ISRCTN ISRCTN43648350
DOI https://doi.org/10.1186/ISRCTN43648350
Secondary identifying numbers EU 101; NTR217
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
31/03/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr D Delawi
Scientific

University Medical Center Utrecht
Department of Orthopaedics
G05.228
PO Box 85500
Utrecht
3508 GA
Netherlands

Phone +31 (0)30 2509001
Email d.delawi@chir.azu.nl

Study information

Study designMulticentre randomised double-blinded active-controlled parallel-group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleOsigraft Study: a prospective, randomised, controlled, multicentre, (pilot) study of Osigraft® in instrumented posterolateral fusions
Study objectivesIt is postulated that the use of Osigraft® will prove beneficial in the treatment of patients requiring decompression and instrumented lumbar spinal fusion while eliminating the pain and morbidity associated with harvesting of autograft bone from the iliac crest.
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedDegenerative disc disease (DDD), spondylolisthesis
InterventionAll subjects will receive decompression and posterolateral spinal fusion via instrumented pedicle fixation. There will be two arms: a treatment arm with Osigraft® and local autograft and a control arm using autogenous bone graft from the iliac crest.
Intervention typeProcedure/Surgery
Primary outcome measureIn order for a patient to be classified as a success, the patients has to meet all of the criteria mentioned below:
1. Radiographic demonstration of spinal fusion
2. Oswestry Disability Index improvement of at least 20% from the pre-treatment visit
3. No revisions, removals or supplemental fixations may occur
4. Absence of a serious investigational-product -related adverse event during the course of the study
5. No unresolved neurological deficits at the final examination that were not present prior to study treatment
6. No decreases in neurological status at the final examination from the preoperative evaluation
Secondary outcome measuresNot provided at time of registration
Overall study start date14/07/2004
Completion date16/10/2006

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants150
Key inclusion criteria1. Diagnosis of degenerative and/or isthmic spondylolisthesis and/or degenerative disc disease (DDD) at the levels of L3-S1 with:
1.1. Lumbar instability of at least 2 to 3 mm translation in standing standard radiographs, or
1.2. At least 2 to 3 mm translation in flexion extension radiograms and/or angulation motion defined as greater than 15° at L3-L4 level, greater than 18° at L4-L5 level, and greater than 17° at L5-S1 spine level
2. Leg and/or back pain with one or more of the following phenomena: radiculopathy, sensory deficit, motor weakness, reflex pathology, neurogenic claudication
3. The subject has been non-responsive to at least 6 months of non-operative treatment prior to study enrolment
4. The subject has a preoperative Oswestry Disability Index of 30 - 100
5. Fusion of only one lumbar level in the L-3 to S-1 region is indicated
6. The subject has no history of previous fusion attempt(s) to the affected spinal level
7. The subject is willing and able to understand, sign and date the study specific patient informed consent, which has been approved by the Institutional Review Board
8. The subject agrees to comply with post-operative clinical and radiographic evaluations and required rehabilitation regimen
9. Age: the subject is skeletally mature between 18 and 80 years of age
10. Gender: both males and females can be included in the study
Key exclusion criteria1. The subject has gross instability as a result of degenerative and/or isthmic spondylolisthesis and/or DDD that requires multiple levels fusion (an example would be exclusion of grade IV spondylolisthesis)
2. The subject is severely osteoporotic/osteopenic as manifested by the presence of a history of osteoporotic spine fractures and/or medical treatment for osteoporosis and/or such changes on the AP/lateral radiographs that will make the surgeon decide to exclude this patient from any form of pedicle fixation
3. The subject has an active spinal and/or systemic infection
4. The subject has a systemic disease or condition, which would affect his/her ability to participate in the study requirements or the ability to evaluate the efficacy of the investigational product (i.e. active malignancy, neuropathy)
5. The subject is a prisoner, a transient or has been treated for alcohol and/or drug abuse in an inpatient substance abuse program within six months prior to proposed study enrolment
6. The subject has participated in clinical trials evaluating investigational devices, pharmaceuticals or biologics within 3 months of enrolment in the study
7. The subject is a woman who intends to bear children within 1 year of enrolling in the study (e.g. is not post-menopausal, has not had a hysterectomy, is not on long term oral contraception)
8. The subject is morbidly obese (defined as weight greater than 60 percent over the recommended ideal weight as described in the 1996 Metropolitan Height and Weight Tables for Men and Women, Appendix B)
9. The subject has a known sensitivity to any component of Osigraft®
10. The subject is known to require at the time of treatment, additional surgery to the lumbar spinal region within the next six months
11. Patients who have in the last year been prescribed systemic corticosteroids
Date of first enrolment14/07/2004
Date of final enrolment16/10/2006

Locations

Countries of recruitment

  • Netherlands

Study participating centre

University Medical Center Utrecht
Utrecht
3508 GA
Netherlands

Sponsor information

University Medical Centre Utrecht (UMCU) (Netherlands)
University/education

PO Box 85500
Utrecht
3508 GA
Netherlands

Website http://www.umcutrecht.nl/zorg/
ROR logo "ROR" https://ror.org/04pp8hn57

Funders

Funder type

Industry

Stryker Nederland BV (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 19/08/2013 Yes No